Chicago—A Phase III head-to-head trial of bosutinib and imatinib for first-line treatment of chronic myeloid leukemia (CML) associated bosutinib with faster and deeper responses. However, like other second-generation tyrosine kinase inhibitors (TKIs), bosutinib was not tolerated as well as imatinib.
In CML, “bosutinib has improved efficacy relative to imatinib. The primary end point of MMR [major molecular response] was met” in the trial, called BFORE, reported Jorge E. Cortes,